Bloodwork Before Starting NAD+

Why Baseline Bloodwork Matters for NAD+

Nicotinamide adenine dinucleotide is a coenzyme that sits at the center of cellular energy metabolism, serving as the primary electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It also functions as a required substrate for SIRT1 and the other sirtuin enzymes that regulate mitochondrial biogenesis, DNA repair, and epigenetic gene silencing. When you raise NAD+ levels through supplementation, you are shifting the activity of these metabolic and epigenetic regulators simultaneously. That means hepatic function, glucose metabolism, and systemic inflammation can all move in response to therapy. Without a pre-protocol snapshot of those systems, your provider cannot distinguish a therapeutic shift from a pathological one. Baseline bloodwork transforms follow-up panels from isolated numbers into a meaningful trajectory.

What to Test Before Starting

Three categories of labs establish your pre-protocol baseline for NAD+ therapy: hepatic function, metabolic markers, and inflammatory status.

For hepatic function, draw Liver Enzymes and specifically ALT/AST before your first dose. NAD+ plays a direct role in hepatocyte metabolism, and supplementation is expected to normalize transaminase levels over time. Elevated ALT or AST at baseline may indicate pre-existing liver stress from alcohol use, medication burden, or fatty liver disease — conditions that need their own evaluation before you layer on a protocol that will further alter hepatic NAD+ pools. Normal baseline values give your provider a clean reference to confirm that therapy is not introducing strain.

On the metabolic side, draw Fasting Glucose before starting. NAD+ directly influences insulin signaling through SIRT1-mediated deacetylation of insulin receptor substrates, and supplementation is expected to normalize fasting glucose in individuals with impaired metabolic regulation. A baseline fasting glucose value establishes where your insulin sensitivity stands before NAD+ begins modulating it.

For inflammatory status, draw hs-CRP as your systemic inflammation marker. NAD+ repletion downregulates NF-kB-driven inflammatory gene expression, and hs-CRP is the most accessible measure of that shift. An already-elevated hs-CRP at baseline tells your provider about your current inflammatory load and may change how aggressively they monitor during therapy. Request all baseline labs fasted and drawn in the morning for the most consistent and comparable values across follow-up panels.

What to Retest and When

At four weeks into your NAD+ protocol, draw NAD+ Levels to confirm that supplementation is actually raising intracellular NAD+ stores. This is the earliest timepoint where a measurable increase is expected, and a flat result at four weeks suggests an absorption or dosing problem worth investigating.

At eight weeks, retest hs-CRP to confirm the expected decrease in systemic inflammation. This is the window where NAD+-driven suppression of inflammatory signaling should produce a visible shift in CRP values compared to your baseline draw.

At twelve weeks, draw HOMA-IR to assess whether insulin sensitivity has improved. HOMA-IR integrates fasting glucose and fasting insulin into a single insulin resistance score, and NAD+ supplementation is expected to normalize this value through sustained SIRT1 activation over the course of the protocol.

After completing your protocol, repeat the full panel to confirm that metabolic and inflammatory markers have settled into their new range. Discuss the post-protocol timeline with your prescribing provider, as concurrent medications and pre-existing metabolic conditions influence how quickly biomarkers stabilize.

Red Flags — When to Pause and Retest

If you have active cancer or a history of recent malignancy, the theoretical concern that NAD+ repletion may fuel tumor cell metabolism warrants serious discussion with your oncologist before starting or continuing therapy. If you are undergoing chemotherapy, NAD+ supplementation may interfere with agents that depend on NAD+ depletion as part of their mechanism. If you are a chronic alcohol user, the timing of NAD+ supplementation relative to alcohol intake matters, and your provider should evaluate hepatic function before proceeding. If mid-protocol labs show rising liver enzymes or worsening metabolic markers rather than the expected normalization, pause the protocol and consult your provider before resuming.

How This Fits Your Broader Protocol

NAD+ is frequently combined with other compounds in structured longevity and metabolic protocols. If you are stacking substances, each one may carry its own biomarker monitoring requirements. Review the full NAD+ contraindications page before finalizing your stack, and use the interaction checker to screen for conflicts between NAD+ and any concurrent medications or supplements.